PHAT

Phathom Pharmaceuticals' stock has experienced volatility over the past six months. The share price saw a significant increase of 365.50% from May 5, 2025, to May 1, 2026, but decreased by 26.7% from January 1, 2026, to May 9, 2026. Recent financial results have played a role, with the company reporting its Q1 2026 earnings on April 30, 2026. Phathom Pharmaceuticals more than doubled its revenue from Q1 2025 to Q1 2026, and its Q1 2026 revenue of $58.3 million exceeded analyst estimates. The company also narrowed its Q1 net loss to US$30.37 million from US$94.32 million a year earlier. Phathom reaffirmed its full-year 2026 net revenue guidance of $320 million to $345 million and anticipates achieving operating profitability, excluding stock-based compensation, starting in the third quarter of 2026. An FDA correction to the Orange Book listing confirmed 10 years of regulatory exclusivity for VOQUEZNA tablets through May 3, 2032.